194 related articles for article (PubMed ID: 21983313)
1. Allopurinol as a cardiovascular drug.
Kelkar A; Kuo A; Frishman WH
Cardiol Rev; 2011; 19(6):265-71. PubMed ID: 21983313
[TBL] [Abstract][Full Text] [Related]
2. Allopurinol as a therapeutic option in cardiovascular disease.
Okafor ON; Farrington K; Gorog DA
Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655
[TBL] [Abstract][Full Text] [Related]
3. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure.
Mellin V; Isabelle M; Oudot A; Vergely-Vandriesse C; Monteil C; Di Meglio B; Henry JP; Dautreaux B; Rochette L; Thuillez C; Mulder P
Eur Heart J; 2005 Aug; 26(15):1544-50. PubMed ID: 15872033
[TBL] [Abstract][Full Text] [Related]
4. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
[TBL] [Abstract][Full Text] [Related]
5. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition.
Harzand A; Tamariz L; Hare JM
Congest Heart Fail; 2012; 18(3):179-82. PubMed ID: 22587748
[TBL] [Abstract][Full Text] [Related]
6. Uric acid: role in cardiovascular disease and effects of losartan.
Alderman M; Aiyer KJ
Curr Med Res Opin; 2004 Mar; 20(3):369-79. PubMed ID: 15025846
[TBL] [Abstract][Full Text] [Related]
7. The role of urate and xanthine oxidase inhibitors in cardiovascular disease.
George J; Struthers AD
Cardiovasc Ther; 2008; 26(1):59-64. PubMed ID: 18466421
[TBL] [Abstract][Full Text] [Related]
8. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options.
Doehner W; Landmesser U
Semin Nephrol; 2011 Sep; 31(5):433-40. PubMed ID: 22000650
[TBL] [Abstract][Full Text] [Related]
9. Allopurinol reduces neointimal hyperplasia in the carotid artery ligation model in spontaneously hypertensive rats.
Yamamoto Y; Ogino K; Igawa G; Matsuura T; Kaetsu Y; Sugihara S; Matsubara K; Miake J; Hamada T; Yoshida A; Igawa O; Yamamoto T; Shigemasa C; Hisatome I
Hypertens Res; 2006 Nov; 29(11):915-21. PubMed ID: 17345792
[TBL] [Abstract][Full Text] [Related]
10. Heart failure, oxidative stress and allopurinol.
Biagi P; Abate L
Monaldi Arch Chest Dis; 2005 Mar; 64(1):33-7. PubMed ID: 16128162
[TBL] [Abstract][Full Text] [Related]
11. [Allopurinol and its role in the treatment of sarcopenia].
Ferrando B; Olaso-Gonzalez G; Sebastia V; Viosca E; Gomez-Cabrera MC; Viña J
Rev Esp Geriatr Gerontol; 2014; 49(6):292-8. PubMed ID: 25131431
[TBL] [Abstract][Full Text] [Related]
12. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk.
Mercuro G; Vitale C; Cerquetani E; Zoncu S; Deidda M; Fini M; Rosano GM
Am J Cardiol; 2004 Oct; 94(7):932-5. PubMed ID: 15464681
[TBL] [Abstract][Full Text] [Related]
13. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Siu YP; Leung KT; Tong MK; Kwan TH
Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency.
Torres RJ; Prior C; Puig JG
Metabolism; 2007 Sep; 56(9):1179-86. PubMed ID: 17697859
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome.
McGaurn SP; Davis LE; Krawczeniuk MM; Murphy JD; Jacobs ML; Norwood WI; Clancy RR
Pediatrics; 1994 Dec; 94(6 Pt 1):820-3. PubMed ID: 7970996
[TBL] [Abstract][Full Text] [Related]
16. Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors.
Packer M
J Card Fail; 2020 Nov; 26(11):977-984. PubMed ID: 32890737
[TBL] [Abstract][Full Text] [Related]
17. Allopurinol therapy of ischemic heart disease with infarct extension.
Parmley LF; Mufti AG; Downey JM
Can J Cardiol; 1992 Apr; 8(3):280-6. PubMed ID: 1576562
[TBL] [Abstract][Full Text] [Related]
18. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
George J; Carr E; Davies J; Belch JJ; Struthers A
Circulation; 2006 Dec; 114(23):2508-16. PubMed ID: 17130343
[TBL] [Abstract][Full Text] [Related]
19. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress.
George J; Struthers AD
Vasc Health Risk Manag; 2009; 5(1):265-72. PubMed ID: 19436671
[TBL] [Abstract][Full Text] [Related]
20. Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest.
Clancy RR; McGaurn SA; Goin JE; Hirtz DG; Norwood WI; Gaynor JW; Jacobs ML; Wernovsky G; Mahle WT; Murphy JD; Nicolson SC; Steven JM; Spray TL
Pediatrics; 2001 Jul; 108(1):61-70. PubMed ID: 11433055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
